zavegepant
zavegepant: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
zavegepant evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could zavegepant → PFE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| PFIZER INC (PFE) Reported 2023-03-09 · Current development: unknownSource | Approved |
| PFIZER INC (PFE) Reported 2023-03-09 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department
Primary endpoint: Pain relief at 2 hours without rescue medication
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with zavegepant?
zavegepant has dated SEC/FDA relationship records for PFIZER INC.
How many clinical trials involve zavegepant?
BioSniper tracks 1 clinical trial involving zavegepant.
What is zavegepant's latest FDA decision?
The most recent tracked FDA decision for zavegepant is Approval for 1 INDICATIONS AND USAGE ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ( 1 ), dated March 9, 2023.